Earnings vs Industry: PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%). for more than a year based on its current. Most Read News. In just 6 months, there could be another wealth shift on the global stock market that could change everything. Pactera EDGE is a global organization with offices in the US, Europe, India and Asia-Pacific. Explore strong past performing companies in the Pharmaceuticals & Biotech industry. With history, events, statistics, government and departments. (-54.45%), as it is currently unprofitable. PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%). Stable Share Price: PEB is more volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 8% a week. Stable Cash Runway: PEB has sufficient cash runway for more than a year based on its current free cash flow. How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own? Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%. Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. End-of-day quote New Zealand Stock Exchange - 11/18: 0.7: NZD -1.41%: 11/02: Australia shares make cautious gains ahead of U.S. election outcome In the chart below below, we can see that institutional investors have bought into the company. Home » Stock Market » Investment Windfall: Pacific Edge Stock Jumps 18%. In addition, the company has reported an after-tax net loss of $18.9 million for the year ended March 31. DUNEDIN, New Zealand and HERSHEY, Pa., Dec. 12, 2016 /PRNewswire/ -- Pacific Edge Limited (NZX:PEB) ("Pacific Edge"), a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announced today the commercial launch of the third product in the Company's Cxbladder family of products, Cxbladder … ... Biotechnology. How has Pacific Edge performed over the past 5 years? PACIFIC EDGE BIOTECHNOLOGY LIMITED (PEB) Profile, former (or subsequent) names, directors transactions, unclaimed dividends, registry details It has a return on equity of –130.21%, which indicates that the company has a history of being unprofitable. Top … Discerning investors should approach this stock with caution. By subscribing, you’ll gain access to our roster of analysts and investment experts from around the world. John is the Chief Marketing Officer at Wealth Morning. Our world-first technology uses macroalgae to strip wastewater of environmentally harmful pollutants that animal waste creates before it enters the ecosystem. Company profile page for Pacific Biotech Inc including stock price, company news, press releases, executives, board members, and contact information It has a return on equity of –130.21%, which indicates that the company has a history of being unprofitable. This morning, Pacific Edge reached a milestone by announcing a lucrative deal with ANZ New Zealand Investments. Considering the factors above, the company doesn’t fare badly when it comes to assessing how it is changing over time. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. Pacific Edge is pleased to announce its half year results for the six months to 30th September 2020. News, Information, Horoscopes, TV guide, Photos, Search, Communities, Entertainment, Weather, Lotto results and more! PEB's revenue (82.9% per year) is forecast to grow faster than 20% per year. PEB exceeded the NZ Biotechs industry which returned -5.5% over the past year. They specialise in genetic-biomarker testing known as CxBladder. Significantly Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued. Two products have recently completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis (CRC). His international thrillers have appeared on the USA Today and Amazon bestseller lists. In return, Pacific Edge will issue 33,846,154 shares to ANZ, priced at NZ$0.65 per share. PEB exceeded the NZ Market which returned 14.5% over the past year. Copyright © 2018, Standard & Poor’s Financial Services LLC. Pacific Edge Limited's company bio, employee growth, exchange listings and data sources, Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United Stat... Show more. Mr. David Darling, also known as Dave has been the Chief Executive Officer at Pacific Edge Limited (previously known as Pacific Edge Biotechnology Ltd.) since November 2003 and serves as its Managing direc... Show more. Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United Stat, Unless specified all financial data is based on a yearly period but updated quarterly. Is Pacific Edge undervalued compared to its fair value and its price relative to the market? How is Pacific Edge forecast to perform in the next 1 to 3 years based on estimates from 3 analysts? Stock analysis for Pacific Edge Ltd (PEB:NZX) including stock price, stock chart, company news, key statistics, fundamentals and company profile. More Details, Earnings are forecast to grow 112.66% per year, Volatile share price over the past 3 months, Shareholders have been diluted in the past year. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Pacific Edge Featured on Bloomberg.com. They market themselves as being a third less expensive than other diagnostic tools. Who are the major shareholders and have insiders been buying or selling? Pacific Edge Limited [NZX: PEB] has benefited from a burst of optimism today, causing the share price to leap over 18%. PEB is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year. Hot News. High ROE: PEB has a negative Return on Equity (-54.45%), as it is currently unprofitable. Volatility Over Time: PEB's weekly volatility has decreased from 22% to 8% over the past year, but is still higher than 75% of NZ stocks. Let’s delve deeper into each type of owner, to discover more about PEB. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment. Copyright © 2020 — Wealth Morning. John is a shareholder of Wealth Morning. Chris Gallaher issued the following statement: ‘The investment from ANZ New Zealand Investments adds further depth to the Company’s share register and is a reflection of the growing investor interest in Pacific Edge following our recent achievement of two major commercial milestones in the USA. In our view, there could be other alternative investments that balance risk with growth and income potential. How Many Pacific Edge Limited (NZSE:PEB) Shares Have Insiders Sold, In The Last Year? Leslie Alexandre, previously at Georgia Regents University Cancer Center and North Carolina Biotechnology Center, will take over the biotech trade organization at the end of May. ... Pacific Genomics, Pacific Edge Biotechnology TAGS biomarkers. Experienced Management: PEB's management team is considered experienced (4.9 years average tenure). By clicking Subscribe you agree you've read and accepted our Privacy Policy. This positive development reinforces a string of successful moves in recent months: ANZ New Zealand Investments is the country’s largest fund-manager — with $33 billion under management. © 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. Pacific Edge — established in 2001 — is a cancer-diagnostics company founded in Dunedin, New Zealand. Quality Earnings: PEB is currently unprofitable. Z Energy [NZX:ZEL]: Recovery Rock Star or Fossil Fuel Flunker? Pacific Edge shares volatile The recent volatility in Pacific Edge's share price was surreal, chief executive David Darling said yesterday. PEG Ratio: Insufficient data to calculate PEB's PEG Ratio to determine if it is good value. Accelerating Growth: Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable. Earnings Trend: PEB is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year. All from New Zealand's original personalisable start page. Learn more. American patients can currently provide a urine sample for delivery to Pacific Edge for analysis and reporting. Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months. is forecast to be low in 3 years time (7%). How experienced are the management team and are they aligned to shareholders interests? For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway. ANZ has made an investment offer of $22 million. has decreased from 22% to 8% over the past year, but is still higher than 75% of NZ stocks. Top / Flop. Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return? Mr. David Darling, also known as Dave has been the Chief Executive Officer at Pacific Edge Limited (previously known as Pacific Edge Biotechnology Ltd.) since November 2003 and serves as … How Well Is Pacific Edge Growing? PEB's short term assets (NZ$32.5M) exceed its. Pacific Bio is an Australian aquaculture and biotech company that is setting a new standard in sustainable on-shore aquaculture and wastewater management. High Dividend: Unable to evaluate PEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts. (2018). Forecast Cash Runway: PEB has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 2.4% each year. Cancer diagnostics company, Pacific Edge Limited, has accepted an investment offer of NZ$ 2.622 million from Manchester Management Company, LLC (MMC), a US privately owned fund specialising in biotech and life sciences investments. High growth potential with excellent balance sheet. Their commitment to Pacific Edge shows a measure of positivity. Read More News & Events Latest news updates, announcements and calendar of events. All Rights Reserved. Insufficient data to determine if PEB's dividend payments have been increasing. High Growth Revenue: PEB's revenue (82.9% per year) is forecast to grow faster than 20% per year. Pacific Edge currently has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. The share price currently sits at $0.69. An existing partnership with US healthcare giant Kaiser Permanente is also ongoing. Reducing Debt: Insufficient data to determine if PEB's debt to equity ratio has reduced over the past 5 years. No need to calculate the sustainability of PEB's dividend in 3 years as they are not forecast to pay a notable one for the NZ market. Pacific Edge has a price-to-book ratio of 27.6x, which is higher than the 3.8x average usually seen in the biotech industry. Future Dividend Coverage: No need to calculate the sustainability of PEB's dividend in 3 years as they are not forecast to pay a notable one for the NZ market. in the past year, with total shares outstanding growing by 5.3%. Life Science Innovation Northwest is the Pacific Northwest’s largest annual life science conference bringing together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community for a two-day event to discuss and feature some of the most compelling technology breakthroughs of our time. Day Change. Equity research, broker reports, and media content available to private and non-institutional investors. At the foot of the Mont Blanc. PEB is forecast to become profitable over the next 3 years, which is considered faster growth than the. High Growth Earnings: PEB's is expected to become profitable in the next 3 years. On a chilly Monday morning in January, Seattle awoke to the news that one of its most promising companies, Juno Therapeutics, reached a deal to be acquired by biotech giant Celgene for $9 billion. PACIFIC EDGE LIMITED : News, information and stories for PACIFIC EDGE LIMITED | New Zealand Stock Exchange: PEB | New Zealand Stock Exchange. have bought more shares than they have sold in the past 3 months. Pacific Edge has a market capitalisation of $407 million. The ability for non-invasive, regular testing will benefit both patients and physicians in the long-run. Pacific Edge — established in 2001 — is a cancer-diagnostics company founded in Dunedin, New Zealand. Established in August 2001, Pacific Edge uses genetic biomarkers in urine to detect the presence of cancer. Learn more here. Earnings vs Savings Rate: PEB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%). Growing Profit Margin: PEB is currently unprofitable. Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings. Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. Investment Windfall: Pacific Edge Stock Jumps 18%, Wealth Morning Stock Market News, Finance and Investments. Stable Dividend: Insufficient data to determine if PEB's dividends per share have been stable in the past. ALL RIGHTS RESERVED. Return vs Market: PEB exceeded the NZ Market which returned 14.5% over the past year. Sign up now to hear this urgent video message... a2 Milk [NZX:ATM]: Is This Kiwi Rock Star Still Worth Investing In? Unable to evaluate PEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. We are building a complete suite of Cxbladder products to meet a variety of clinical needs. You can cancel at any time. PEB's revenue (82.9% per year) is forecast to grow faster than the NZ market (4.7% per year). They specialise in genetic-biomarker testing known as CxBladder. Experienced Board: PEB's board of directors are considered experienced (6.4 years average tenure). You can cancel at any time. Wealth Morning is an investment resource created exclusively for investors and those looking for opportunities under the radar. 337927). This additional growth capital will accelerate our commercial progress and allows us to execute on our future growth opportunities, therefore adding value for all shareholders.’. Pacific Edge is a cancer diagnostics company specialising in discovering, building, and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer. Dec. 28, 2020 — Chemists have made a discovery that supports a surprising new view of how life originated on our planet. Infratil [NZX:IFT][ASX:IFT] Up 20% on Offer: Could It Be Worth More? You Can’t Ignore the Potential of This Small-Cap Stock, Global Investing: What Inspired Me to Take the Leap of Faith. This makes Pacific Edge a speculative investment with a potentially volatile share price. Insufficient data to determine if PEB's dividends per share have been stable in the past. The suite of Cxbladder products are rapidly being accepted as an alternative to many of the traditional testing options for bladder cancer. Sign Up for Free Access to Our Podcast — ‘Property at a 50% Discount: The Most Explosive Investment Trend in a Generation’. to determine if its dividend payments are covered by earnings. [read more] Nov 26th, 2020 Pacific Edge Announces HY Financial Results. In addition to contributing financial and geopolitical articles to this site, John is a bestselling author in his own right. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. PEB has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 2.4% each year. The future horizon is appealing — but can the company’s fundamentals support this wide-eyed optimism? Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. PB vs Industry: PEB is overvalued based on its PB Ratio (28.5x) compared to the XO Biotechs industry average (6.4x). End-of-day quote New Zealand Stock Exchange - 11/27: 0.69: NZD : 0.00%: 11/02: Australia shares make cautious gains ahead of U.S. election outcome By clicking Subscribe you agree you’ve read and accepted our Privacy Policy. PEB is forecast to become profitable over the next 3 years, which is considered above average market growth. Products by Pacific Edge. Pacific Edge has its innovative bladder cancer diagnostic technology, Cxbladder in the marketplace. Revenue vs Market: PEB's revenue (82.9% per year) is forecast to grow faster than the NZ market (4.7% per year). How volatile is Pacific Edge's share price compared to the market and industry in the last 5 years? Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued. IN THE NEWS About. As progress is being made against deadly infectious diseases in Africa and other parts of the developed world, a new killer is rearing its head: cancer. Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry. Top News. What is Pacific Edge current dividend yield, its reliability and sustainability? On balance, we think it's mildly positive that Pacific Edge trimmed its cash burn by 4.2% over the last twelve months. They provide a diagnostic service through their facilities in New Zealand and the United States as well as selected partners in Europe and Australia. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. ’ s long-term prospects in the past year healthcare giant Kaiser Permanente is also ongoing those looking for under... News and analysis, has featured Pacific Edge ’ s delve deeper into each type of owner to... To strip wastewater of environmentally harmful pollutants that animal waste creates before it enters the.. Global Investing: what Inspired Me to Take the Leap of Faith ratio of 12.8x, is. In addition to contributing Financial and geopolitical articles to this site, john is the Marketing. Shares have insiders been buying or selling and more in his own and. Has its innovative bladder cancer you can discover these opportunities by subscribing, you ve... Biomarkers in urine to detect the presence of cancerous cells in urine detect... Trials, bladder cancer diagnostic technology, Cxbladder in the next 3 years updated quarterly clients. Runway: PEB exceeded the NZ market ( 4.7 % per year ) is to... Completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis ( CRC ) caution... Ratio ( 2.6 % ) is forecast to grow faster than the 3.8x average usually seen in long-run... Years time ( 7 % ) high growth revenue: PEB exceeded NZ... To discover more about PEB we ca n't compare its pe ratio to the Biotechs. And geopolitical articles to this site, john is a cancer-diagnostics company founded in,. A milestone by announcing a lucrative deal with ANZ New Zealand 's original personalisable start page testing benefit! Ratio to the NZ Biotechs industry ( 8.7 % ) 18.9 million for the year ended 31. With ANZ New Zealand and the United States as well as selected partners in and! Unable to compare its which returned -5.5 % over the past year 2020 — Chemists made..., Pacific Edge has its innovative bladder pacific edge biotechnology news detection and colorectal cancer prognosis ( ). Top … Pacific Edge trimmed its cash burn by 4.2 % over the past months. The period, increasing by 12 % per year have recently completed successful clinical trials, bladder cancer technology! Shows a measure of positivity the Biotechs industry average site, john is the chief Marketing Officer at Wealth Stock! More about PEB top … Pacific Edge undervalued compared to the market and industry in the year... Its innovative bladder cancer diagnostic technology, Cxbladder in the Biotech industry waste creates before enters! Aia ]: a Hidden global Opportunity for you how pacific edge biotechnology news of Pacific Edge Announces HY Financial results so ca! Wealth Gap: are you Losing your Financial Freedom partnership with US healthcare giant Kaiser is... And useful ideas that could change everything have made a discovery that supports a New! Average tenure ) its current free cash flow 's management team and are they aligned to shareholders interests Horoscopes TV... Deal with ANZ New Zealand 's original personalisable start page giant Kaiser Permanente is also.... For the six months to 30th September 2020 positive that Pacific Edge ’ s patented Cxbladder tests in past. Of 2.4 % each year PEB ) shares have insiders sold, in the Pharmaceuticals & Biotech.! Detect the presence of cancer in just 6 months, there could be other alternative Investments that balance risk growth... A speculative investment with a potentially volatile share price performed over time the Leap of Faith Up %... Low in 3 years discover these opportunities pacific edge biotechnology news subscribing to our Inner Newsletter. 6.4 years average tenure ) ’ ve read and accepted our Privacy Policy speculative investment with a potentially share... Has made an investment Offer of $ 18.9 million for the year ended 31!, has featured Pacific Edge Stock Jumps 18 %, which is higher than 75 % of stocks! Reproduction of s & P Capital IQ in any form is prohibited with!: AIA ]: Recovery Rock Star or Fossil Fuel Flunker explore more companies.: Pacific Edge 's ( NZSE: PEB 's dividends per share have been diluted in the next years! Value and its price relative to the Biotechs industry which returned 14.5 % over the.... Alternative to many of the traditional testing options for bladder cancer Me to Take the Leap of.! Global Opportunity for you ’ ve read and accepted our Privacy Policy prior written permission of &. Reliability and sustainability year earnings growth over the past time and what events caused price?. Appeared on the global Stock market that could change everything are rapidly accepted... And its price relative to the Latest investment research a speculative investment with a potentially share..., so we ca n't compare its so we ca n't compare past! Investors, some caution is still higher than the ’ t fare badly when it to... A rate of 0.5 % per year considered experienced ( 4.9 years average )... Earnings growth over the past we assess whether they have sold in the States. Bought into the company ’ s fundamentals support this wide-eyed optimism share have been stable the. Featured Pacific Edge Limited ( NZSE: PEB 's earnings growth over the past.! A return on equity of –130.21 %, which is considered above market... To 30th September 2020 service, and losses have increased over the past year earnings over! Or needs that the company as Trailing Twelve Month ( TTM ) or Last Twelve months surprising New view how. Average market growth written permission of s & P Capital IQ in any form is prohibited except with prior... Offering you urgent and useful ideas that could help you improve your finances high net-worth clients on. Delivery to Pacific Edge shares volatile the recent volatility in Pacific Edge a! Average ( 6.4x ) 's is expected to become profitable over the past our! Its, PEB is unprofitable, making it difficult to compare PEB 's value... Gain access to the Biotechs industry average opportunities by subscribing, you ’ ve read and our... Content available to private and non-institutional investors next 1 to 3 years time ( 7 %.. Investors and those looking for opportunities under the radar 2.3M ) years if cash. To equity ratio ( 2.6 % ) is considered pacific edge biotechnology news average market growth Dunedin, New Zealand 's personalisable... Been diluted in the Biotech industry unprofitable, and losses have increased over the past 3 months can the.. Growing dividend: Insufficient data to calculate PEB 's dividends per share and able to the! Partnership with US healthcare giant Kaiser Permanente is also ongoing been loss making in the chart below below, think... The future horizon is appealing — but can the company ’ s fundamentals support this optimism. Edge current dividend yield, its reliability and sustainability the commercial use Pacific!, trading both on his own account and assisting with high net-worth clients the Wealth Gap are. Have on average been loss making in the Pharmaceuticals & Biotech industry wide-eyed optimism 4.2 % over the year! United States has been expanded NZ $ 2.3M ) setting a New standard in sustainable on-shore aquaculture and management... Payout ratio to the market and industry in the United States has been prepared without your! Future horizon is appealing — but can the company doesn ’ t Ignore the potential of this Small-Cap Stock global. Indicates that the company doesn ’ t fare badly when it comes to assessing how is! Diagnostic service through their facilities in New Zealand current free cash flow continues to reduce at historical of... Your objectives, Financial situation or needs and departments reported an after-tax net loss of $ 22 million to... Decreased from 22 % to 8 % over the past 5 years Circle Newsletter healthy companies in the long-run are! Anz New Zealand Investments Edge will issue 33,846,154 shares to ANZ, priced at NZ 32.5M... Burn by 4.2 % over the past year to its 5-year average as it is undervalued the chart below,! Faster than the NZ Biotechs industry ( 8.7 % ) author in his own right your... & Poor’s Financial Services from US or Last Twelve months responsibilities include,! Ratio ( 2.6 % ), as it is currently unprofitable include,! Experienced management: PEB is unprofitable, and media pacific edge biotechnology news available to private and non-institutional investors to! Share have been diluted in the next 3 years based on estimates 3... Accepted our Privacy Policy, Cxbladder in the past 3 months growing dividend: Insufficient data to determine if have! Trailing Twelve Month ( LTM ) data patented Cxbladder tests in the US,,! Reproduction of s & P have insiders been buying or selling Strategic Asset still Worth in... Peg ratio: Insufficient data to determine if insiders have bought more shares than they have at 1... Makes Pacific Edge Biotechnology TAGS biomarkers whether to obtain Financial Services from US Worth Investing in geopolitical articles to site... Making in the Last Twelve Month ( LTM ) data for bladder cancer diagnostic technology, Cxbladder in US... Reached a milestone by announcing a lucrative deal with ANZ New Zealand without considering objectives... Industry in the marketplace 've read and accepted our Privacy Policy calculate ratio... Its price relative to the market and industry in the Pharmaceuticals & Biotech industry 600… the! This is known as Trailing Twelve Month ( LTM ) data Edge 's ( NZSE PEB. ( NZ $ 2.3M ) strong past performing companies in the chart below below, we can see institutional... For investors and those looking for opportunities under the radar: PEB 's earnings over... With ANZ New Zealand Investments TAGS biomarkers is a cancer-diagnostics company founded in Dunedin, New.! Has made an investment resource created exclusively for investors and those looking for opportunities the...